<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10225170</article-id><article-id pub-id-type="pmcid-ver">PMC10225170.1</article-id><article-id pub-id-type="pmcaid">10225170</article-id><article-id pub-id-type="pmcaiid">10225170</article-id><article-id pub-id-type="manuscript-id">NIHMS1888454</article-id><article-id pub-id-type="pmid">37028102</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2023.109851</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1888454</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1888454</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Incidence of suicide and self-harm among people with opioid use disorder and the impact of opioid agonist treatment: a retrospective data linkage study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Colledge-Frisby</surname><given-names initials="S">Samantha</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="N">Nicola</given-names></name><degrees>MSc</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Degenhardt</surname><given-names initials="L">Louisa</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hickman</surname><given-names initials="M">Matthew</given-names></name><degrees>PhD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Padmanathan</surname><given-names initials="P">Prianka</given-names></name><degrees>PhD</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Santo</surname><given-names initials="T">Thomas</given-names><suffix>Jr</suffix></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Farrell</surname><given-names initials="M">Michael</given-names></name><degrees>FRCP</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gisev</surname><given-names initials="N">Natasa</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>National Drug Research Institute, Melbourne, Australia</aff><aff id="A2"><label>2</label>National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia</aff><aff id="A3"><label>3</label>Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom</aff><author-notes><fn fn-type="present-address" id="FN1"><p id="P1">Address: Burnet Institute, 85 Commercial Rd, Melbourne, VIC, Australia</p></fn><fn fn-type="con" id="FN2"><p id="P2">Contributors</p><p id="P3"><bold>Samantha Colledge-Frisby</bold>: Conceptualisation, Methodology, Visualisation, Writing-Original draft preparation, Writing-Reviewing and Editing. <bold>Nicola Jones</bold>: Data curation, Methodology, Formal analysis, Writing-Reviewing and Editing. <bold>Prianka Padmanathan:</bold> Writing-Reviewing and Editing. <bold>Thomas Santo Jr:</bold> Writing-Reviewing and Editing. <bold>Matthew Hickman:</bold> Writing-Reviewing and Editing. <bold>Michael Farrell:</bold> Writing-Reviewing and Editing. <bold>Louisa Degenhardt:</bold> Conceptualisation, Methodology, Writing-Reviewing and Editing, Supervision, Funding acquisition. <bold>Natasa Gisev</bold>: Conceptualisation, Methodology, Writing-Reviewing and Editing, Supervision.</p></fn><corresp id="CR1"><label>*</label>Corresponding author: Samantha Colledge-Frisby, <email>s.colledge@curtin.edu.au</email></corresp><fn fn-type="COI-statement" id="FN3"><label>7.</label><p id="P53">Conflict of interest</p><p id="P54">All other authors have no conflicts of interest to declare.</p></fn><fn fn-type="COI-statement" id="FN4"><p id="P55">Conflict of interest statement: Incidence of suicide and self-harm among people with opioid use disorder and the impact of opioid agonist treatment: a retrospective data linkage study</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>23</day><month>3</month><year>2023</year></pub-date><volume>246</volume><issue-id pub-id-type="pmc-issue-id">436827</issue-id><fpage>109851</fpage><lpage>109851</lpage><pub-history><event event-type="nihms-submitted"><date><day>11</day><month>05</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 12:25:14.010"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1888454.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P4">Rates of suicide and self-harm are elevated among people with opioid use disorder (OUD). This study examined incidence of self-harm and suicide among people who have entered OAT and assessed the impact of different OAT exposure periods on these events.</p></sec><sec id="S2"><title>Method:</title><p id="P5">We conducted a retrospective population-based cohort study of all OAT recipients (N=45,664) in New South Wales, Australia (2002&#8211;2017), using linked administrative data. Incidence rates of self-harm hospitalisations and suicide deaths were estimated per 1000 person-years (PY). The first 28 days of an OAT episode, &#8805;29 days on OAT, the first 28 days off OAT, and &#8805;29 days off OAT (maximum four years post-OAT) were exposure periods. Poisson regression models with generalised estimating equations estimated the adjusted incidence rate ratios (ARR) of self-harm and suicide by OAT exposure periods, adjusting for covariates.</p></sec><sec id="S3"><title>Results:</title><p id="P6">There were 7482 hospitalisations (4148 individuals) for self-harm and 556 suicides, equating to incidence rates of 19.2 (95% confidence intervals [CI]=18.8&#8211;19.7) and 1.0 (95%CI=0.9&#8211;1.1) per 1000 PY, respectively. Opioid overdose was implicated in 9.6% of suicides and 28% of self-harm hospitalisations. Compared to &#8805;29 days on OAT, the incidence rate of suicide was elevated in the 28 days following OAT cessation (ARR=17.4 [95%CI=11.7&#8211;25.9]), and the rate of self-harm hospitalisations was elevated during the first 28 days of OAT (ARR=2.2 [95%CI=1.9&#8211;2.6]) and the 28 days after leaving OAT (ARR=2.7 [95%CI=2.3&#8211;3.2]).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P7">OAT may reduce suicide and self-harm risk among people with OUD; however, OAT initiation and cessation are critical periods for targeting self-harm and suicide prevention interventions.</p></sec></abstract><kwd-group><kwd>Suicide</kwd><kwd>self-harm</kwd><kwd>opioid agonist treatment</kwd><kwd>opioid use disorder</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>